Our results were consistent across all sensitivity analyses, including a more restrictive definition of CKD, a cohort covering a 36-month period, and using the ACC/AHA and American Diabetes Association guidelines to determine ACE-inhibitor/ARB eligibility (Table S7-S9). This evidence concerns the gene ACE and chronic kidney disease.